Skip to main content

Publications

What type of publication do you want to show?

2023

Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.

Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.. PharmacoEconomics - open, 7(6), 1015. doi:10.1007/s41669-023-00462-7

DOI
10.1007/s41669-023-00462-7
Journal article

Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15

Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. doi:10.1007/s41669-023-00439-6

DOI
10.1007/s41669-023-00439-6
Journal article

Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]

Greenhalgh, J., Mahon, J., Bryning, S., Chaplin, M., Beale, S., Boland, A., . . . Basu, B. (2023). Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]. Retrieved from https://www.nice.org.uk/guidance/gid-ta10920/documents/committee-papers

Report

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Houten, R., Fleeman, N., Mahon, J., Chaplin, M., Edwards, K., Beale, S., . . . Palmieri, C. (2023). Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN. doi:10.1007/s41669-023-00405-2

DOI
10.1007/s41669-023-00405-2
Journal article

Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.

Bresnahan, R., Duarte, R., Mahon, J., Beale, S., Chaplin, M., Bhattacharyya, D., . . . Boland, A. (2023). Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.. Health technology assessment (Winchester, England), 27(10), 1-115. doi:10.3310/kgju3398

DOI
10.3310/kgju3398
Journal article

2022

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin

Pillay, S., Steingart, K. R., Davies, G. R., Chaplin, M., De Vos, M., Schumacher, S. G., . . . Theron, G. (2022). Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (5). doi:10.1002/14651858.CD014841.pub2

DOI
10.1002/14651858.CD014841.pub2
Journal article

2021

2020

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Stainthorpe, A., Fleeman, N., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Syndikus, I. (2020). Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 4(4), 563-574. doi:10.1007/s41669-020-00203-0

DOI
10.1007/s41669-020-00203-0
Journal article

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Greenhalgh, J., Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., . . . Goodson, N. (2020). Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: Ixekizumab for treating axial spondyloarthritis after NSAIDs[ID1532]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/

Report

Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation

Duarte, R., Stainthorpe, A., Greenhalgh, J., Richardson, M., Nevitt, S., Mahon, J., . . . Takwoingi, Y. (2020). Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(3), 1-+. doi:10.3310/hta24030

DOI
10.3310/hta24030
Journal article

2019

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., Dundar, Y., . . . Shenoy, A. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19(1). doi:10.1186/s12885-019-6369-7

DOI
10.1186/s12885-019-6369-7
Journal article

Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation

Duarte, R., Stainthorpe, A., Mahon, J., Greenhalgh, J., Richardson, M., Nevitt, S., . . . Takwoingi, Y. (2019). Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation. PLOS ONE, 14(12). doi:10.1371/journal.pone.0226671

DOI
10.1371/journal.pone.0226671
Journal article

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Fleeman, N., Bagust, A., Duarte, R., Richardson, M., Nevitt, S., Boland, A., . . . Thorp, N. (2019). Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(3), 293-302. doi:10.1007/s41669-018-0114-z

DOI
10.1007/s41669-018-0114-z
Journal article

Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck

Greenhalgh, J., Mahon, J., Chaplin, M., Nevitt, S., Boland, A., Beale, S., . . . Shaw, R. (2019). Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck: Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (17/56/06). NICE website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10181/documents/committee-papers

Report

Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies

Richardson, M., Kirkham, J. J., Dwan, K. M., Sloan, D. J., Davies, G., & Jorgensen, A. (2019). Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies. BMJ OPEN, 9(7). doi:10.1136/bmjopen-2019-030212

DOI
10.1136/bmjopen-2019-030212
Journal article

Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer

Greenhalgh, J., Mahon, J., Chaplin, M., Beale, S., Boland, A., Lambe, T., . . . Palmieri, C. (2019). Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer: Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer (128748). NICE website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10433/documents/committee-papers

Report

2018

Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer

Fleeman, N., Mahon, J., Chaplin, M., Boland, A., Beale, S., De Sousa Rego Vieira Duarte, R., . . . Green, J. (2018). Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer: Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non- small-cell lung cancer (17/141/08). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta621/documents/committee-papers

Report

Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12)

Fleeman, N., Stainthorpe, A., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Isabel, S. (2018). Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12): Brentuximab vedotin for treating relapsed or refractory CD30- positive cutaneous T-cell lymphoma (17/56/12). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta577/documents/committee-papers

Report

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Stainthorpe, A., Greenhalgh, J., Bagust, A., Richardson, M., Boland, A., Beale, S., . . . Palmer, D. (2018). Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1153-1163. doi:10.1007/s40273-018-0646-1

DOI
10.1007/s40273-018-0646-1
Journal article

Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Fleeman, N., Abdulla, A., Bagust, A., Beale, S., Richardson, M., Stainthorpe, A., . . . Palmer, D. (2018). Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36(3), 289-299. doi:10.1007/s40273-017-0592-3

DOI
10.1007/s40273-017-0592-3
Journal article

2017

Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer

Greenhalgh, J. (n.d.). Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (ID1059). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta535/documents/committee-papers

Report

Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer

Greenhalgh, J., Bagust, A., Stainthorpe, A., Chaplin, M., Boland, A., De Sousa Rego Vieira Duarte, R., . . . Palmer, D. (2017). Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (14/90/01). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta476/documents/committee-papers

Report

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy

Greenhalgh, J. (n.d.). Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy (ID970). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta520/documents/committee-papers

Report

2016

Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review

Aslam, R. W., Bates, V., Dundar, Y., Hounsome, J., Richardson, M., Krishan, A., . . . Robinson, L. (2016). Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review. Health Technology Assessment, 20(77). doi:10.3310/hta20770

DOI
10.3310/hta20770
Journal article

GenoType® MTBDR<i>sl</i> assay for resistance to second-line anti-tuberculosis drugs

Theron, G., Peter, J., Richardson, M., Warren, R., Dheda, K., & Steingart, K. R. (2016). GenoType® MTBDR<i>sl</i> assay for resistance to second-line anti-tuberculosis drugs. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (9). doi:10.1002/14651858.CD010705.pub3

DOI
10.1002/14651858.CD010705.pub3
Journal article

Integrated management of childhood illness (IMCI) strategy for children under five

Gera, T., Shah, D., Garner, P., Richardson, M., & Sachdev, H. S. (2016). Integrated management of childhood illness (IMCI) strategy for children under five. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (6). doi:10.1002/14651858.CD010123.pub2

DOI
10.1002/14651858.CD010123.pub2
Journal article

The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation

Fleeman, N., Mahon, J., Bates, V., Dickson, R., Dundar, Y., Dwan, K., . . . Shaw, B. N. J. (2016). The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 20(30), 1-67. doi:10.3310/hta20300

DOI
10.3310/hta20300
Journal article

Cluster Randomised Trials in Cochrane Reviews: Evaluation of Methodological and Reporting Practice

Richardson, M., Garner, P., & Donegan, S. (2016). Cluster Randomised Trials in Cochrane Reviews: Evaluation of Methodological and Reporting Practice. PLOS ONE, 11(03), 14 pages. doi:10.1371/journal.pone.0151818

DOI
10.1371/journal.pone.0151818
Journal article

Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)

Yotsu, R. R., Richardson, M., & Ishii, N. (n.d.). Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd012118

DOI
10.1002/14651858.cd012118
Journal article

Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma

Greenhalgh, J., Mahon, J., Beale, S., Boland, A., Krishan, A., Chaplin, M., . . . Steven, N. (2016). Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma: Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (12/50/01). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta396/history

Report

Talimogene laherparepvec for treating metastatic melanoma

Fleeman, N., Bagust, A., Boland, A., Beale, S., Chaplin, M., Krishan, A., . . . Payne, M. (2016). Talimogene laherparepvec for treating metastatic melanoma: Talimogene laherparepvec for treating metastatic melanoma (14/206/04). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-tag509/documents/committee-papers-2

Report

2015

Health system and community level interventions for improving antenatal care coverage and health outcomes

Mbuagbaw, L., Medley, N., Darzi, A. J., Richardson, M., Garga, K. H., & Ongolo-Zogo, P. (2015). Health system and community level interventions for improving antenatal care coverage and health outcomes. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (12). doi:10.1002/14651858.CD010994.pub2

DOI
10.1002/14651858.CD010994.pub2
Journal article

Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab

Fleeman, N., Bagust, A., Chaplin, M., Krishan, A., Boland, A., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab: Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (14/177/07). NICE Website. Retrieved from https://www.nice.org.uk/

Report

Effects of financial incentives for treatment supporters on tuberculosis treatment outcomes in Swaziland: a pragmatic interventional study

Kliner, M., Canaan, M., Ndwandwe, S. Z., Busulwa, F., Welfare, W., Richardson, M., . . . Wright, J. (2015). Effects of financial incentives for treatment supporters on tuberculosis treatment outcomes in Swaziland: a pragmatic interventional study. INFECTIOUS DISEASES OF POVERTY, 4. doi:10.1186/s40249-015-0059-8

DOI
10.1186/s40249-015-0059-8
Journal article

A mismatch between population health literacy and the complexity of health information: an observational study

Rowlands, G., Protheroe, J., Winkley, J., Richardson, M., Seed, P. T., & Rudd, R. (2015). A mismatch between population health literacy and the complexity of health information: an observational study. BRITISH JOURNAL OF GENERAL PRACTICE, 65(635), E379-E386. doi:10.3399/bjgp15X685285

DOI
10.3399/bjgp15X685285
Journal article

Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab

Greenhalgh, J., Mahon, J., Chaplin, M., Krishan, A., Aslam, R., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab: Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab (14/177/06). NICE website. Retrieved from https://www.nice.org.uk/guidance/TA366/documents/committee-papers

Report

Mosquito repellents for malaria prevention

Maia, M. F., Kliner, M., Richardson, M., Lengeler, C., & Moore, S. J. (n.d.). Mosquito repellents for malaria prevention. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd011595

DOI
10.1002/14651858.cd011595
Journal article

Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation

Greenhalgh, J., Longworth, L., Crossan, C., Singh, J., Bagust, A., Boland, A., . . . Hall, M. (2015). Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (14/14/01). NICE website. Retrieved from https://www.nice.org.uk/

Report

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation

Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Hockenhull, J., . . . Marshall, E. (2015). Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 19(47), I-133. doi:10.3310/hta19470

DOI
10.3310/hta19470
Journal article

Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis

Protogerou, C., Fleernan, N., Dwan, K., Richardson, M., Dundar, Y., & Hagger, M. S. (2015). Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis. BEHAVIOUR RESEARCH AND THERAPY, 73, 151-164. doi:10.1016/j.brat.2015.08.004

DOI
10.1016/j.brat.2015.08.004
Journal article

Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis

Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Fleeman, N., . . . Fisher, M. (2015). Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 19(29), 1-+. doi:10.3310/hta19290

DOI
10.3310/hta19290
Journal article

2014

The diagnostic accuracy of the GenoType® MTBDR<i>sl</i> assay for the detection of resistance to second-line anti-tuberculosis drugs

Theron, G., Peter, J., Richardson, M., Barnard, M., Donegan, S., Warren, R., . . . Dheda, K. (2014). The diagnostic accuracy of the GenoType® MTBDR<i>sl</i> assay for the detection of resistance to second-line anti-tuberculosis drugs. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (10). doi:10.1002/14651858.CD010705.pub2

DOI
10.1002/14651858.CD010705.pub2
Journal article

Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

Greenhalgh, J., Bagust, A., Beale, S., Boland, A., Chaplin, M., Dwan, K., . . . Hall, M. (2014). Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (14/15/01). NICE website. Retrieved from https://www.nice.org.uk/

Report

Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma

Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2014). Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma: Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma (12/54). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta321/history

Report

EFFICACY OF PSYCHOLOGICAL INTERVENTIONS TO REDUCE DISTRESS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES: A META-ANALYSIS

Protogerou, C., Fleeman, N. F., Dwain, K. D., Richardson, M. R., Dundar, Y. D., & Dickson, R. D. (2014). EFFICACY OF PSYCHOLOGICAL INTERVENTIONS TO REDUCE DISTRESS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES: A META-ANALYSIS. In INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE Vol. 21 (pp. S63). Retrieved from https://www.webofscience.com/

Conference Paper